KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Total Current Liabilities (2016 - 2026)

Gsk has reported Total Current Liabilities over the past 18 years, most recently at -$30.2 billion for Q1 2026.

  • For Q1 2026, Total Current Liabilities fell 15.25% year-over-year to -$30.2 billion; the TTM value through Mar 2026 reached -$30.2 billion, down 15.25%, while the annual FY2025 figure was -$28.5 billion, 202.17% down from the prior year.
  • Total Current Liabilities for Q1 2026 was -$30.2 billion at Gsk, down from -$28.5 billion in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $27.8 billion in Q4 2024 and troughed at -$47.6 billion in Q2 2022.
  • A 5-year average of -$17.6 billion and a median of -$26.2 billion in 2025 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 75.88% in 2022 and later crashed 273.01% in 2023.
  • Year by year, Total Current Liabilities stood at $26.8 billion in 2022, then dropped by 2.26% to $26.1 billion in 2023, then increased by 6.5% to $27.8 billion in 2024, then crashed by 202.17% to -$28.5 billion in 2025, then fell by 6.27% to -$30.2 billion in 2026.
  • Business Quant data shows Total Current Liabilities for GSK at -$30.2 billion in Q1 2026, -$28.5 billion in Q4 2025, and -$28.8 billion in Q3 2025.